Abstract: An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules. The composition is designed to release hydroccodone in a way such that the increase in hydrocodone exposure in hepatically impaired patients is not clinically significant. The oral dosage units are supplied as part of a kit, which also includes a primary package and a package insert all sold as a commercially marketed product.
Type:
Grant
Filed:
October 28, 2019
Date of Patent:
July 28, 2020
Assignee:
Persion Pharmaceuticals LLC
Inventors:
Andrew Hartman, Christopher M. Rubino, Cynthia Y. Robinson
Abstract: An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules. The composition is designed to release hydrocodone in a way such that the increase in hydrocodone exposure in hepatically impaired patients is not clinically significant. The oral dosage units are supplied as part of a kit, which also includes a primary package and a package insert all sold as a commercially marketed product.
Type:
Grant
Filed:
July 23, 2018
Date of Patent:
October 29, 2019
Assignee:
Persion Pharmaceuticals LLC
Inventors:
Andrew Hartman, Christopher M. Rubino, Cynthia Y. Robinson
Abstract: An extended release composition for an analgesic active pharmaceutical ingredient which may be an opioid, preferably hydrocodone as the only active ingredient. The extended release composition preferably comprises a extended release composition which may be in the form of beads contained in an oral dosage form such as gelatin capsules. The composition is designed to release hydrocodone in a way such that the increase in hydrocodone exposure in hepatically impaired patients is not clinically significant. The oral dosage units are supplied as part of a kit, which also includes a primary package and a package insert all sold as a commercially marketed product.
Type:
Grant
Filed:
October 24, 2014
Date of Patent:
June 18, 2019
Assignee:
Persion Pharmaceuticals LLC
Inventors:
Andrew Hartman, Christopher M. Rubino, Cynthia Y. Robinson